Family of small molecule drugs to treat diabetes complications
A class of novel small molecule compounds to attenuate cell and tissue damage due to diabetes was developed at UMKC, and preclinical data shows highly significant reversal of hyperglycemia mediated cell and tissue damage in late-stage diabetes.
The invention addresses an urgent need for pharmaceutical drug development as a first-in-class technology complementary to already marketed drugs. Our invention reduces the effects of diabetes (tissue damage, loss of function such as vision, sensation using peripheral nerves, kidney and heart function). Existing drugs attempt to reduce the causes of diabetes. Since these approaches are currently only moderately effective there is both an urgent clinical need and potentially significant market for our invention, for type 1 and 2 diabetics, as well as patients with metabolic syndrome and “pre-“diabetes. Our patent pending technology addresses this urgent clinical need for the most important areas of diabetic complications including, but not limited to diabetic retinopathy, neuropathy, nephropathy, cardiomyopathy and “type 3” diabetes.